US FDA's Biologics Center May Get Its Day In PDUFA VII

Multiple stakeholders call for CBER to receive more prescription drug user fee funds amid growing cell and gene therapy popularity.

The bright lights of the prescription drug user fee program may be ready to shift more toward the US Food and Drug Administration’s biologics center.

Multiple industry and stakeholder groups indicated that a tidal wave of work is bearing down on the Center for Biologics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Already a subscriber?